SE0002320D0 - Malignant tumors - Google Patents

Malignant tumors

Info

Publication number
SE0002320D0
SE0002320D0 SE0002320A SE0002320A SE0002320D0 SE 0002320 D0 SE0002320 D0 SE 0002320D0 SE 0002320 A SE0002320 A SE 0002320A SE 0002320 A SE0002320 A SE 0002320A SE 0002320 D0 SE0002320 D0 SE 0002320D0
Authority
SE
Sweden
Prior art keywords
malignant tumors
compounds
formula
racemate
tautomer
Prior art date
Application number
SE0002320A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0002320A priority Critical patent/SE0002320D0/xx
Publication of SE0002320D0 publication Critical patent/SE0002320D0/xx
Priority to HK03100644.7A priority patent/HK1049830A1/zh
Priority to JP2001533112A priority patent/JP3950337B2/ja
Priority to CZ20021293A priority patent/CZ298534B6/cs
Priority to DE60034240T priority patent/DE60034240T2/de
Priority to CA002386775A priority patent/CA2386775C/en
Priority to AU11851/01A priority patent/AU775057B2/en
Priority to HR20020353A priority patent/HRP20020353A2/hr
Priority to DK00973329T priority patent/DK1224172T3/da
Priority to HU0203238A priority patent/HU229072B1/hu
Priority to NZ518296A priority patent/NZ518296A/xx
Priority to PCT/SE2000/002055 priority patent/WO2001030758A1/en
Priority to AT00973329T priority patent/ATE358668T1/de
Priority to IL14878200A priority patent/IL148782A0/xx
Priority to KR1020027005077A priority patent/KR100597938B1/ko
Priority to UA2002032524A priority patent/UA73748C2/uk
Priority to KR1020067008739A priority patent/KR100674160B1/ko
Priority to ES00973329T priority patent/ES2280258T3/es
Priority to US09/694,757 priority patent/US6395750B1/en
Priority to EP00973329A priority patent/EP1224172B1/en
Priority to YUP-232/02A priority patent/RS51019B/sr
Priority to CNB008147574A priority patent/CN100390148C/zh
Priority to PL354540A priority patent/PL199781B1/pl
Priority to EEP200200207A priority patent/EE200200207A/xx
Priority to IL148782A priority patent/IL148782A/en
Priority to IS6329A priority patent/IS2750B/is
Priority to NO20021932A priority patent/NO323320B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0002320A 1999-10-25 2000-06-21 Malignant tumors SE0002320D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PL354540A PL199781B1 (pl) 1999-10-25 2000-10-24 Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
EEP200200207A EE200200207A (et) 1999-10-25 2000-10-24 Kinoliiniderivaatide kasutamine vähivastase ravimi valmistamiseks, ühendite saamine ning neid sisaldavad farmatseutilised kompositsioonid
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
KR1020027005077A KR100597938B1 (ko) 1999-10-25 2000-10-24 악성 종양의 치료용 약제
CZ20021293A CZ298534B6 (cs) 1999-10-25 2000-10-24 Lécivo k lécbe maligních nádoru
DE60034240T DE60034240T2 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren
CA002386775A CA2386775C (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
AU11851/01A AU775057B2 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
HR20020353A HRP20020353A2 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
DK00973329T DK1224172T3 (da) 1999-10-25 2000-10-24 Medikamenter til behandling af ondartede tumorer
HU0203238A HU229072B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
NZ518296A NZ518296A (en) 1999-10-25 2000-10-24 N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer
HK03100644.7A HK1049830A1 (zh) 1999-10-25 2000-10-24 用於治療惡性腫瘤的藥物
AT00973329T ATE358668T1 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren
IL14878200A IL148782A0 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
JP2001533112A JP3950337B2 (ja) 1999-10-25 2000-10-24 悪性腫瘍治療薬
UA2002032524A UA73748C2 (en) 1999-10-25 2000-10-24 Medicaments for the treatment of cancer
KR1020067008739A KR100674160B1 (ko) 1999-10-25 2000-10-24 악성 종양의 치료용 약제
ES00973329T ES2280258T3 (es) 1999-10-25 2000-10-24 Farmacos para el tratamiento de tumores malignos.
US09/694,757 US6395750B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumors
EP00973329A EP1224172B1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours
YUP-232/02A RS51019B (sr) 1999-10-25 2000-10-24 Lekovi za lečenje malignih tumora
CNB008147574A CN100390148C (zh) 1999-10-25 2000-10-24 用于治疗恶性肿瘤的药物
IL148782A IL148782A (en) 1999-10-25 2002-03-20 Drugs for the treatment of malignant tissues
IS6329A IS2750B (is) 1999-10-25 2002-04-02 Leiðarafesting
NO20021932A NO323320B1 (no) 1999-10-25 2002-04-24 Medikament egnet til behandling av ondartede tumorer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (1)

Publication Number Publication Date
SE0002320D0 true SE0002320D0 (sv) 2000-06-21

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors

Country Status (21)

Country Link
EP (1) EP1224172B1 (cs)
JP (1) JP3950337B2 (cs)
KR (2) KR100674160B1 (cs)
AT (1) ATE358668T1 (cs)
AU (1) AU775057B2 (cs)
CA (1) CA2386775C (cs)
CZ (1) CZ298534B6 (cs)
DE (1) DE60034240T2 (cs)
DK (1) DK1224172T3 (cs)
EE (1) EE200200207A (cs)
ES (1) ES2280258T3 (cs)
HK (1) HK1049830A1 (cs)
HR (1) HRP20020353A2 (cs)
HU (1) HU229072B1 (cs)
IL (2) IL148782A0 (cs)
IS (1) IS2750B (cs)
NO (1) NO323320B1 (cs)
NZ (1) NZ518296A (cs)
SE (1) SE0002320D0 (cs)
UA (1) UA73748C2 (cs)
WO (1) WO2001030758A1 (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ES2628026T3 (es) 2004-06-24 2017-08-01 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
EP2687512A1 (en) 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
BRPI0713694A2 (pt) 2006-06-12 2012-10-30 Teva Pharma composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
DK2234485T3 (da) 2007-12-20 2014-02-10 Teva Pharma Stabile laquinimod-præparater
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
CN103153959A (zh) * 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1，2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
KR20150091077A (ko) * 2012-11-07 2015-08-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드의 아민염
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
PL3041472T3 (pl) * 2014-09-23 2017-08-31 Active Biotech Ab Chinolinokarboksyamidy do stosowania w leczeniu szpiczaka mnogiego
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
KR102525805B1 (ko) * 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
PE20231098A1 (es) * 2019-11-28 2023-07-18 Bayer Ag Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune
CA3168070A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
EP4153576A4 (en) * 2020-05-21 2024-06-19 StemSynergy Therapeutics, Inc. NOTCH INHIBITORS AND THEIR USES
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
MX2023013301A (es) 2021-05-25 2023-12-04 Active Biotech Ab Una pluralidad de particulas tasquinimod y su uso.
CN117500790A (zh) 2021-07-02 2024-02-02 活跃生物技术有限公司 含有他喹莫德的药物产品和用于评估所述产品的纯度的方法
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
AU2022421214A1 (en) * 2021-12-20 2024-07-04 The Johns Hopkins University Compounds for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
KR20060054496A (ko) 2006-05-22
DK1224172T3 (da) 2007-08-13
CZ20021293A3 (cs) 2002-07-17
AU775057B2 (en) 2004-07-15
IL148782A (en) 2007-05-15
HUP0203238A3 (en) 2003-05-28
HU229072B1 (en) 2013-07-29
CZ298534B6 (cs) 2007-10-31
KR100597938B1 (ko) 2006-07-06
HK1049830A1 (zh) 2003-05-30
IL148782A0 (en) 2002-09-12
HRP20020353A2 (en) 2005-10-31
WO2001030758A1 (en) 2001-05-03
EP1224172A1 (en) 2002-07-24
DE60034240T2 (de) 2007-12-20
UA73748C2 (en) 2005-09-15
KR100674160B1 (ko) 2007-01-24
KR20020043646A (ko) 2002-06-10
NZ518296A (en) 2003-06-30
EE200200207A (et) 2003-06-16
JP3950337B2 (ja) 2007-08-01
NO20021932L (no) 2002-06-21
DE60034240D1 (de) 2007-05-16
CA2386775C (en) 2004-07-13
NO20021932D0 (no) 2002-04-24
ATE358668T1 (de) 2007-04-15
IS2750B (is) 2011-08-15
HUP0203238A2 (hu) 2003-01-28
NO323320B1 (no) 2007-03-12
CA2386775A1 (en) 2001-05-03
JP2003512454A (ja) 2003-04-02
AU1185101A (en) 2001-05-08
IS6329A (is) 2002-04-02
ES2280258T3 (es) 2007-09-16
EP1224172B1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
SE0002320D0 (sv) Malignant tumors
YU23202A (sh) Lekovi za tretman malignih tumora
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
SE9904505D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
GB0112348D0 (en) Compounds
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
SE0103836D0 (sv) Novel compounds
ATE316083T1 (de) Adamantanderivate
EA200101046A1 (ru) Производные индигоидных бис-индолов
SE9901875D0 (sv) Novel compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
EP1453812A4 (en) CYTOTOXIC AGENTS
ATE238981T1 (de) Antitumorwirkstoffe
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
SE0400708D0 (sv) New compounds and use thereof
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
BR0116123A (pt) Carbazóis antitumorais
BRPI0415355A (pt) triarilimidazóis